

NI Formulary: Chapter 6 Endocrine

Please refer to the full version of the Formulary for further advice and information.

Therapeutic Area	Drug choice
Insulins Rapid (analogue) Immediate with food	Apidra® Fiasp® Humalog® (100,200) Novorapid®
Insulins Short 15 to 30 mins before food	Actrapid® Humulin S®
Insulins Intermediate (Isophane) Same time every day	Humulin I®
Insulins Long (analogue) Same time every day	Abasaglar® Lantus® Toujeo® Tresiba® (100,200)
Insulins Biphasic Up to 15 mins before food	Humalog® Mix (25,50) Novomix® 30
Insulins Biphasic Isophane Up to 30 mins before food	Humulin® M3
Biguanides	1 Metformin tablets 500mg
Sulfonylureas	1 Gliclazide tablets 40mg, 80mg
Dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitors)	1 Sitagliptin tablets 25mg, 50mg, 100mg
	2 Linagliptin tablets 5mg
Glitazones (thiazolidinediones)	1 Pioglitazone tablets 15mg, 30mg, 45mg
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors	1 Canagliflozin 100mg, 300mg tablets
	1 Dapagliflozin 10mg tablets
	1 Empagliflozin 10mg, 25mg tablets
GLP-1 mimetic (injectable) Prescribe by brand name	1 Daily injection : liraglutide (Diaviv®) injection 6mg/mL 3ml pre-filled pens Weekly injection: 1 Dulaglutide (Trulicity®) 0.75mg/0.5ml, 1.5mg/0.5ml, 3mg/0.5ml and 4.5mg/0.5ml solution for injection pre filled pens or 1 Semaglutide (Ozempic®) 0.25mg/0.19ml, 0.5mg/0.37ml, 1mg/0.74ml solution for injection pre-filled pens 1 Oral tablets: Semaglutide (Rybelsus®) 3mg, 7mg 14mg tablets
Treatment of hypoglycaemia	1 Glucose (oral) or 1 GlucaGen® Hypokit 1mg powder and solvent for solution for injection (glucagon) 1 Glucose intravenous infusion

NI Formulary: Chapter 6 Endocrine

Please refer to the full version of the Formulary for further advice and information.

Therapeutic Area	Drug choice
Hypothyroidism	1 Levothyroxine tablets 25micrograms, 50micrograms, 100 micrograms
Hyperthyroidism a) Antithyroid drugs b) Beta-blockers	1 Carbimazole tablets 5mg, 20mg To be initiated on specialist advice 1 Propranolol tablets 10mg, 40mg 1 Propranolol MR capsules 80mg, 160mg
Corticosteroids a) Replacement therapy	<u>Replacement therapy (mineralocorticoid)</u> 1 Fludrocortisone tablets 100micrograms <u>Glucocorticoid therapy</u> Hydrocortisone tablets 10mg
b) Glucocorticoid therapy	1 Prednisolone tablets 1mg, 5mg or 1 Dexamethasone tablets 500micrograms, 2mg; injection 3.8mg/mL; injection 3.3mg/mL or 1 Hydrocortisone sodium succinate 100mg powder and solvent for solution for injection vials or 1 Methylprednisolone tablets 2mg, 4mg, 16mg, 100mg 1 Methylprednisolone sodium succinate (Solu-Medrone®) powder and solvent for injection vials 40mg, 125mg, 500mg, 1g 1 Intramuscular depot: Methylprednisolone acetate (Depo-Medrone®) suspension for injection vials 40mg/mL, 80mg/2mL, 120mg/3mL
HRT for menopausal symptoms a) Women who have not had a hysterectomy	1 <u>Sequential combined (oral)</u> Elleste-Duet® 1mg, 2mg tablets (estradiol and norethisterone) or Femoston® 1/10, 2/10 tablets (estradiol and dydrogesterone) 1 <u>Sequential combined (transdermal)</u> Evorel® Sequi patches: (combination pack of 4 Evorel® 50 patches [estradiol 50micrograms/24hours] and 4 Evorel® Conti patches [estradiol 50micrograms/24hours]) and norethisterone acetate 170micrograms/24hours) <u>Continuous combined (oral)</u> 1 Bijuve® 1mg/100mg capsules (estradiol 1mg and progesterone 100mg) 1 Femoston® conti 0.5mg/2.5mg tablets; 1mg/5mg tablets (estradiol and dydrogesterone) 1 Indivina® 1mg/2.5mg tablets; 1mg/5mg tablets; 2mg/5mg tablets (estradiol and medroxyprogesterone acetate) <i>Note: only licensed when LMP occurred over 3 years previously</i> 1 Klifem® tablets (estradiol 2mg and norethisterone 1mg)

NI Formulary: Chapter 6 Endocrine

Please refer to the full version of the Formulary for further advice and information.

Therapeutic Area	Drug choice
	<p>① Kliovance® tablets (estradiol 1mg and norethisterone 500micrograms)</p> <p><u>Continuous combined (transdermal)</u></p> <p>① Evorel® Conti patches (estradiol 50micrograms/24hours and norethisterone 170micrograms/24hours (matrix patch))</p>
b) Women who have had a hysterectomy or who have a suitable levonorgestrel intrauterine system (LNG IUS) in situ for < 5 years	<p><u>Unopposed oestrogens (oral)</u></p> <p>① Elleste-Solo® 1mg, 2mg (estradiol) tablets or Zumenon® 1mg, 2mg (estradiol) tablets</p> <p><u>Unopposed oestrogens (transdermal)</u></p> <p>① Evorel® patches 50micrograms (or 25micrograms, 75micrograms, 100micrograms/24 hours) (estradiol)</p> <p><u>Unopposed oestrogens spray</u></p> <p>① Lenzetto® 1.53mg/dose transdermal spray</p> <p><u>Unopposed oestrogens gel</u></p> <p>① Oestrogel® 0.06% gel or</p> <p>① Sandrena® gel sachets 500mcg, 1mg</p>
Drugs for the treatment and management of Osteoporosis (a) Calcium and Vitamin D (b) bisphosphonates	<p>① Adcal-D3® Caplets (750mg/200IU) or</p> <p>① Accrete D3® film-coated tablets (600mg/400IU) or</p> <p>① Accrete D3® One a Day Chewable Tablets (1000 mg / 880 IU)</p> <p>② Adcal-D3® Dissolve effervescent tablets (1500mg /400IU) <i>Reserve for swallowing difficulties</i></p> <p>① Alendronic acid tablets 70mg or</p> <p>① Risedronate sodium tablets 35mg</p>
Acromegaly	<p>The primary treatment of acromegaly is usually pituitary surgery. Management and treatment requires specialist involvement. Please refer to 'Prescribing Notes' in full version of formulary.</p>